Evommune, Inc. (NYSE:EVMN) drew elevated trading interest in the September 2026 session even as shares closed little changed, down 0.19% at $10.54 at last closing. The near-flat session arrived at a sensitive moment for the company, which had guided investors to expect a pivotal …
Few biotechnology debutants have carried as much buzz into the back half of 2026 as Generate Biomedicines, Inc. The AI-driven protein-design company, trading onNasdaqunder the ticker GENB, has lined up an unusually dense run of September investor conferences, and shares closed up 2.14% at …
Apnimed, Inc. (NASDAQ:APMD) has been one of the most talked-about biopharma listings of the summer, arriving on theNasdaqin late July 2026 with a lead candidate aimed at one of medicine's largest undertreated markets: obstructive sleep apnea. After an eventful debut and a fresh set …
American Scientific Resources, Incorporated (OTC:ASFX) is one of the market's true ghost tickers, a onetime medical-device maker whose shares are quoted at essentially nothing and whose corporate paper trail went quiet more than a decade ago. Priced at a hundredth of a penny or …
Barely a month after its market debut, Attovia Therapeutics, Inc. (NASDAQ:ATTO) closed up 1.15% at $22.79 at last closing. The immunology-focused developer priced an upsized offering in early August 2026 and has traded well above its issue price since, offering investors a lesson in …
The prospectus supplement covers the resale of securities by selling shareholders identified in the prospectus.
Few 2026 biotech debutants have commanded the attention that Avalyn Pharma Inc. (NASDAQ:AVLN) has drawn since its spring listing. Shares closed down 3.17% at $33.57 at last closing, a modest pullback that has prompted some holders to revisit the company's rich valuation even as …
BioNTech SE (NASDAQ: BNTX) Chief Executive Officer Sahin Ugur sold 20,500 shares at $96.31 per share on Sep. 10. Following the transaction, he owned 688,209 shares.
Small-cap wellness names can move sharply on modest volume, but Bio Essence Corp (OTC:BIOE) held flat at $0.18 at last closing. The California-based supplement maker has spent 2026 trying to reposition itself, upgrading its market tier and floating anAcquisitionto push into digital health, and …
Cellectis S.A. (NASDAQ: CLLS) announced that it will host a business update call and webcast on September 14, 2026. The event will provide a business update through conference-call and webcast formats.